Peptide Research Hub
Educational reference
Educational reference only. Nothing on this site is medical advice. Many compounds described here are not FDA-approved, lack adequate human evidence, and may be illegal in your jurisdiction. Always consult a licensed clinician.

Sexual Function & Reproductive

Kisspeptin

Metastasis-suppressor KiSS-1

Also known as: Metastin KP-10 KP-54

Evidence: Moderate clinical Disclaimer: Elevated Investigational
Elevated-disclaimer compound. Not approved by the FDA. Evidence is limited to animal models or small human studies. Safety in humans has not been established.

Mechanism & research context

Endogenous neuropeptide that regulates GnRH pulse generation. Studied in Phase 2 trials for hypothalamic amenorrhea and male reproductive disorders.

Safety flags

0 flags

No curator-recorded safety flags for this entry. Absence of recorded flags is not evidence of safety. Many peptides lack adequate human data.

Research papers

16 records

Citation links route to PubMed, Europe PMC, and PMC. Presence of a study is not endorsement. Records are refreshed from PubMed on a regular cadence; rows marked “Live search link” will resolve to a current PubMed search until a full citation has been ingested.

Clinical trials

21 records
  • Live search Live search

    Live ClinicalTrials.gov search: Kisspeptin

    Condition: See live results

    Open on ClinicalTrials.gov ↗
  • NCT00559754 PHASE2 COMPLETED

    An Open Label Study to Assess the Effect of a Combination of Avastin and Docetaxel and Sequential Chemotherapy on Pathological Response in Patients With Primary Operable HER2 Negative Breast Cancer

    Condition: Breast Cancer

    Sponsor: Hoffmann-La Roche

    Open on ClinicalTrials.gov ↗
  • NCT01132404 PHASE1 TERMINATED

    A Phase 1/2, Open Label Study in Men With Prostate Cancer to Assess the Safety. Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448, Administered as a 1-Month Depot, Including a Randomized Portion With a Group Administered Leuprorelin

    Condition: Prostate Cancer; Prostatic Neoplasms

    Sponsor: Millennium Pharmaceuticals, Inc.

    Open on ClinicalTrials.gov ↗
  • NCT01438073 PHASE1 COMPLETED

    Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling

    Condition: Hypogonadotropic Hypogonadism; Healthy Postmenopausal Women; Agonadism

    Sponsor: Massachusetts General Hospital

    Open on ClinicalTrials.gov ↗
  • NCT01667406 PHASE2 COMPLETED

    The Use of the Hormone Kisspeptin in 'in Vitro Fertilisation' (IVF) Treatment

    Condition: Infertility

    Sponsor: Imperial College London

    Open on ClinicalTrials.gov ↗
  • NCT01944475 UNKNOWN

    Follow-up of Girls With Premature Thelarche and Precocious Puberty: a Clinical and Paraclinical Study of Girls With Thelarche and Healthy Controls

    Condition: Precocious Puberty; Excess; Development, Breast

    Sponsor: University of Aarhus

    Open on ClinicalTrials.gov ↗
  • NCT01944488 NA UNKNOWN

    LH Response to GnRH Test in Prepubescent Girls Under 6 Years

    Condition: Precocious Puberty

    Sponsor: University of Aarhus

    Open on ClinicalTrials.gov ↗
  • NCT01952782 PHASE1 COMPLETED

    Neuropeptides in Human Reproduction

    Condition: Hypogonadotropic Hypogonadism

    Sponsor: Massachusetts General Hospital

    Open on ClinicalTrials.gov ↗
  • NCT02514629 PHASE3 COMPLETED

    Randomized, Double-blind, Parallel, Placebo-controlled, Clinical Trial to Assess the Efficacy of Testosterone, Metformin, or Both, for the Treatment of Obesity-induced Male Hypogonadism

    Condition: Hypogonadism; Obesity

    Sponsor: Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

    Open on ClinicalTrials.gov ↗
  • NCT02877992 NA COMPLETED

    Development of a New Diagnostic Tool to Assess Oocyte Quality Based on Tachykinin and Kisspeptin Expression Analysis in Human Granulosa and Cumulus Cells

    Condition: Infertility

    Sponsor: Vida Recoletas Sevilla

    Open on ClinicalTrials.gov ↗
  • NCT03018314 COMPLETED

    Serum Kisspeptin Levels in Infertile Women Due to Anovulatory Cycles, Unexplained Infertility or Male Subfertility: A Prospective Observational Study

    Condition: Infertility, Female; Unexplained Infertility; Anovulation

    Sponsor: Bakirkoy Dr. Sadi Konuk Research and Training Hospital

    Open on ClinicalTrials.gov ↗
  • NCT03286517 PHASE3 COMPLETED

    Changes in the Responsiveness of the Hypothalamic-pituitary-gonadal (HPG) Axis to Kisspeptin-10 Administration During Pubertal Transition in Boys

    Condition: Reproductive Physiological Phenomena

    Sponsor: Ghulam Nabi

    Open on ClinicalTrials.gov ↗
  • NCT03315325 PHASE3 COMPLETED

    Age-dependent Changes in the Responsiveness of Hypothalamic Pituitary Gonadal Axis to Kisspeptin-10 Administration in Men

    Condition: Sterility, Reproductive

    Sponsor: Quaid-e-Azam University

    Open on ClinicalTrials.gov ↗
  • NCT03877939 COMPLETED

    Detection of Kisspeptins and miRNAs in Patients With Non-viable Pregnancy

    Condition: Non-Viable Pregnancy

    Sponsor: Vida Recoletas Sevilla

    Open on ClinicalTrials.gov ↗
  • NCT04012632 COMPLETED

    Polymorphisms in the Kisspeptin/GPR54 Pathway Genes and the Risk of Early Puberty

    Condition: Puberty, Precocious

    Sponsor: Shenzhen Center for Disease Control and Prevention

    Open on ClinicalTrials.gov ↗
  • NCT04532801 PHASE1 WITHDRAWN

    Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Physiologic Mixed Meal Tolerance

    Condition: Insulin; Glucose; Healthy Volunteers; Women; Pregnancy

    Sponsor: Stephanie B. Seminara, MD

    Open on ClinicalTrials.gov ↗
  • NCT04648969 PHASE2 COMPLETED

    Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism

    Condition: Hypogonadotropic Hypogonadism

    Sponsor: Stephanie B. Seminara, MD

    Open on ClinicalTrials.gov ↗
  • NCT04958109 PHASE1 COMPLETED

    Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test

    Condition: Metabolic Diseases

    Sponsor: Massachusetts General Hospital

    Open on ClinicalTrials.gov ↗
  • NCT05633966 PHASE1 COMPLETED

    Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders

    Condition: Hypothalamic Amenorrhea; Hypogonadotropic Hypogonadism

    Sponsor: Stephanie B. Seminara, MD

    Open on ClinicalTrials.gov ↗
  • NCT06204965 NA UNKNOWN

    The Impact of Time-restricted Eating on the Composition of the Intestinal Microbiota and Metabolic and Neurohormonal Parameters of Women With Polycystic Ovary Syndrome

    Condition: Polycystic Ovary Syndrome

    Sponsor: Joanna Bajerska

    Open on ClinicalTrials.gov ↗
  • NCT06501729 NA COMPLETED

    Potential Effect of Oral Kissing Between Two People Against the Decrease in pH

    Condition: Dental Caries; Tooth Demineralization; Teeth Erosion Limited to the Enamel

    Sponsor: Universidad Catolica Santiago de Guayaquil

    Open on ClinicalTrials.gov ↗

Doses reported in studies

0 records
This is not a dosing guide. Entries below are historical metadata transcribed verbatim from a cited clinical-trial protocol, published study, or FDA-approved label. They describe what was administered in a specific study population under medical supervision — they are not recommendations, not common-use guidance, and may not be safe or appropriate outside the cited context. Doses widely discussed in community/anecdotal sources are not shown here; see the safety policy for why.

No study-protocol dose records have been curated for Kisspeptin yet. Absence of records is not evidence of safety — many peptides lack adequate human-trial data in the first place.

Records here are populated from public sources only (ClinicalTrials.gov protocol summaries and FDA-approved labels) and must cite a verifiable source URL. They are not added from forum posts, vendor pages, anecdotal write-ups, or social media.

These entries describe what was studied. They do not tell you what to take, how to reconstitute anything, how to fill a capsule, how often to administer, or where to obtain a compound. If you are considering use of Kisspeptin, those decisions belong with a licensed clinician working from the full label or trial record — not from this summary.

Why this page does not list a dose for self-use

The "Doses reported in studies" section above (when populated) describes what was administered in a cited study or label, under medical supervision, in a specific population. It is not a dosing guide for self-use. Separately, we do not publish anecdotal or community-reported dose ranges, administration methods, vial concentrations, or capsule masses for Kisspeptin. Anecdotal figures for unapproved compounds are not harm-reduction data: they lack denominators for adverse events, cannot account for individual physiology or compound purity, and normalise unsupervised use. See the safety policy for the full reasoning.

If this compound has an FDA-approved label

If a label exists, the regulator-reviewed dosing and administration information is there — read it in the context of a prescriber's evaluation.

Questions worth bringing to a clinician

  • What is the evidence for this compound in someone with my history?
  • What are the realistic, regulator-reviewed alternatives?
  • What would you monitor, and what would make you stop?

If you have already taken a peptide and feel unwell: contact emergency services. In the United States, Poison Control is reachable 24/7 at 1-800-222-1222. Do not wait for a community thread.

Research peptides are not substitutes for medical care. If you are considering any peptide for health purposes, speak with a board-certified physician or endocrinologist first.